FDA Clears Generic Radiodiagnostic for Prostate Cancer Imaging

The U.S. Food and Drug Administration has granted approval for RadioMedix's generic gallium Ga 68 gozetotide injection. This radiodiagnostic agent is utilized in PET imaging to detect prostate-specific membrane antigen-positive lesions in prostate cancer patients. The approval expands the available options for diagnosing and monitoring the disease.